Most Read Articles
15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.

Scleroderma renal crisis uncommon in Asians with systemic sclerosis

01 Sep 2017

Scleroderma renal crisis (SRC) appears to be a rare complication in Thai patients with systemic sclerosis (SSc), but is associated with high mortality, according to a study. Digital gangrene, current prednisolone dose ≥15 mg/day, serum albumin <3 mg/dL and cardiac involvement are independently associated with SRC.

Researchers retrospectively examined the medical records of 608 SSc patients seen at the Division of Rheumatology, Chiang Mai University. Each SRC patient was matched by disease duration (±1 year) with four SSc patients without SRC.

A total of 19 patients developed SRC (63.2 percent with hypertensive renal crisis; 36.8 percent with normotensive renal crisis), yielding an SRC prevalence of 3.13 percent. The mean age was 56.2 years, and median disease duration was 5 months. Majority (89.5 percent) had diffuse cutaneous SSc. There were 15 patients (78.9 percent) who required dialysis and 10 (52.6 percent) who died.

Multivariate conditional logistic regression analysis found SRC to be independently associated with digital gangrene (adjusted odd ratio [AOR], 31.41; 95 percent CI, 1.16 to 852.23; p=0.041), current prednisolone dose ≥15 mg/day (AOR, 31.22; 1.59 to 613.85; p=0.024), serum albumin <3 mg/dL (AOR, 7.97; 1.49 to 42.56; p=0.015) and cardiac involvement (AOR, 6.62; 1.08 to 40.63; p=0.041).

SRC was a major cause of death in patients with SSc, with prevalence rates of 12 to 18 percent in Western countries, until the late 1970s. Since then, the development of angiotensin-converting enzyme inhibitors (ACEI) has greatly helped in improving outcomes in SRC, as well as reducing the frequency of SRC. However, while ACEI has shown efficacy in managing SRC, the morbidities and mortalities from SRC remain high. [Ann Rheum Dis 2007;66:940–4; Semin Arthritis Rheum 2015;44:687–94; Ann Rheum Dis 2010;69:1809–15]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.